Table 4 Summary of mortality amongst exposed and non-exposed T. infestans post-canine treatment bioassaysa
Days post-canine treatment | Triatomines applied to treated dogs | Triatomines applied to control dogs | ||
|---|---|---|---|---|
Proportion (dead/exposed) | Dead/Non-exposed | Dead/Exposed | Dead/Non-exposed | |
Bravecto® | ||||
2 | 1 (42/42) | 0/3 | 0/9 | 0/6 |
7 | 1 (41/41) | 1/4 | 0/14 | 0/1 |
21 | 1 (43/43) | 0/2 | 0/13 | 1/2 |
34 | 1 (36/36) | 1/9 | 0/14 | 0/1 |
51 | 1 (40/40) | 1/5 | 0/15 | 0/0 |
Total | 1 (202/202) | 0.13 (3/23) | 0.0 (0/65) | 0.10 (1/10) |
Comfortis® | ||||
2 | 0.55 (16/29) | 0/17 | 0/14 | 0/1 |
7 | 0.63 (27/43) | 1/4 | 0/9 | 0/6 |
21 | 0.48 (19/40) | 0/5 | 0/14 | 0/1 |
34 | 0.36 (16/44) | 0/2 | 0/14 | 0/1 |
51 | 0.03 (1/38) | 3/8 | 1/14 | 0/1 |
Total | 0.41 (79/194) | 0.11 (4/36) | 0.02 (1/65) | 0.0 (0/10) |
NexGard® | ||||
2 | 0.97 (29/30) | 1/17 | 0/4 | 0/11 |
7 | 1 (32/32) | 0/13 | 0/12 | 0/3 |
21 | 0.95 (38/40) | 0/5 | 0/15 | 0/0 |
34 | 1 (39/39) | 4/6 | 0/15 | 0/0 |
51 | 1 (40/40) | 0/5 | 0/15 | 0/0 |
Total | 0.98 (178/181) | 0.11 (5/46) | 0.0 (0/61) | 0.0 (0/14) |
Total (3 treatments) | 0.11 (12/105) | 0.01 (1/191) | 0.03 (1/34) | |